A STUDY OF ANTI-INFLAMMATORY EFFECT OF RHUSTOXICODENDRON UNDER LABORATORY SETTING AND CLINICAL EVALUATION IN RHEUMATOID ARTHRITIS CASES

RHUS TOXICODENDRON AS A POTENTIAL ANTI-INFLAMMATORY AGENT: EVIDENCE FROM RAW264.7 CELL LINE STUDIES AND CLINICAL TRIAL IN RHEUMATOID ARTHRITIS CASES - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109633

Enrollment

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Rhustoxicodendron: Rhus Toxicodendron 6C potency in appropriate interval. Control Intervention1: Homeopathic Constitutional Medicine: Homoeopathic Constitutional medicine will be admin

Eligibility

Inclusion criteria

Inclusion criteria: 1. Those patients satisfying 2010 ACR/EULAR criteria for Rheumatoid Arthritis. 2. Subjects belonging to both sexes. 3. Patients belonging to the age group 20-70 years

Exclusion criteria

Exclusion criteria: 1. Known cases of malignancies, renal failure, hepatic failure. 2. Pregnant females. 3. Cases with disease activity score 28 value more than 7.5

Design outcomes

Primary

Measure	Time frame
In cell line study Title: To assess anti-inflammatory property of Rhus Toxicodendron Description: To assess cell viability through MTT assay and to assess cytokine expression in RAW 264.7 cell In clinical study Title: Disease Activity Score 28 Description: Disease Activity Score 28 final value - Disease Activity Score 28 initial valueTimepoint: In cell line study Interval:4 week In Clinical study Each case will be reviewed at 3 weeks intervals and will be assessed with Disease Activity Score 28 at the end of 3 month.	—

Measure

Time frame

In cell line study Title: To assess anti-inflammatory property of Rhus Toxicodendron Description: To assess cell viability through MTT assay and to assess cytokine expression in RAW 264.7 cell In clinical study Title: Disease Activity Score 28 Description: Disease Activity Score 28 final value - Disease Activity Score 28 initial valueTimepoint: In cell line study Interval:4 week In Clinical study Each case will be reviewed at 3 weeks intervals and will be assessed with Disease Activity Score 28 at the end of 3 month.

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Mansoor Ali K R

Govt Homeopathic Medical College

drmansoorkr@gmail.com9249337799

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026